Neoantigen Immunogenicity Landscapes and Evolution of Tumor Ecosystems during Immunotherapy with Nivolumab

80 patients with non-small cell lung cancer were enrolled in the biomarker cohort of CheckMate 153, which collected radiographic guided biopsy samples before treatment and during treatment with nivolumab.